Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

研究的高级管理人员对结果表示满意，强调了lumateperone在长期治疗中的潜在益处。这一消息基于新闻稿声明，尚未经独立验证。CAPLYTA在儿科患者中的疗效尚未确立，该药物对老年痴呆相关精神病患者有增加死亡风险的警告，对儿童和年轻成人患者有增加自杀想法和行为风险的警告。

VANCOUVER, British Columbia and ROAD TOWN, British Virgin Islands, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bluestone Resources Inc.

Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...

这一扩张是公司抓住双相抑郁症（BPD）市场机遇策略的一部分。Intra-Cellular还首次对其旗舰产品Caplyta进行了预测，预计未来十年销售额将超过50亿美元。这一估计假设公司在BPD和重度抑郁症（MDD）市场占据领先份额，并预期净价格会有所提升。 高盛预计 ...

This expansion is part of the company's strategy to capitalize on the bipolar depression (BPD) market. Intra-Cellular also introduced a forecast for Caplyta, its flagship product, projecting over $5 ...